Alkermes Valuation
Is ALKS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALKS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALKS ($27.7) is trading below our estimate of fair value ($75.6)
Significantly Below Fair Value: ALKS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALKS?
Key metric: As ALKS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is ALKS's PE Ratio? | |
|---|---|
| PE Ratio | 11.6x |
| Earnings | US$386.95m |
| Market Cap | US$4.52b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | 11.1x |
| PEG Ratio | -0.9x |
Price to Earnings Ratio vs Peers
How does ALKS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 32.7x | ||
HALO Halozyme Therapeutics | 14.8x | 21.1% | US$5.8b |
ACAD ACADIA Pharmaceuticals | 21x | 26.6% | US$2.7b |
EXEL Exelixis | 21.3x | 15.6% | US$9.9b |
ADMA ADMA Biologics | 73.9x | 30.5% | US$5.1b |
ALKS Alkermes | 11.6x | -12.6% | US$4.5b |
Price-To-Earnings vs Peers: ALKS is good value based on its Price-To-Earnings Ratio (11.6x) compared to the peer average (32.7x).
Price to Earnings Ratio vs Industry
How does ALKS's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: ALKS is good value based on its Price-To-Earnings Ratio (11.6x) compared to the US Biotechs industry average (16.8x).
Price to Earnings Ratio vs Fair Ratio
What is ALKS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 11.6x |
| Fair PE Ratio | 15.6x |
Price-To-Earnings vs Fair Ratio: ALKS is good value based on its Price-To-Earnings Ratio (11.6x) compared to the estimated Fair Price-To-Earnings Ratio (15.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$27.70 | US$34.08 +23.0% | 18.2% | US$43.00 | US$21.00 | n/a | 13 |
| Nov ’25 | US$26.47 | US$32.62 +23.2% | 19.8% | US$43.00 | US$21.00 | n/a | 13 |
| Oct ’25 | US$28.83 | US$34.69 +20.3% | 22.1% | US$50.00 | US$21.00 | n/a | 13 |
| Sep ’25 | US$28.45 | US$34.69 +21.9% | 22.1% | US$50.00 | US$21.00 | n/a | 13 |
| Aug ’25 | US$26.86 | US$34.69 +29.2% | 22.1% | US$50.00 | US$21.00 | n/a | 13 |
| Jul ’25 | US$24.39 | US$34.62 +41.9% | 21.8% | US$50.00 | US$21.00 | n/a | 13 |
| Jun ’25 | US$23.40 | US$34.67 +48.1% | 22.6% | US$50.00 | US$21.00 | n/a | 12 |
| May ’25 | US$24.01 | US$34.50 +43.7% | 20.0% | US$50.00 | US$23.00 | n/a | 12 |
| Apr ’25 | US$27.24 | US$34.83 +27.9% | 13.8% | US$43.00 | US$25.00 | n/a | 12 |
| Mar ’25 | US$30.24 | US$34.64 +14.5% | 14.3% | US$43.00 | US$25.00 | n/a | 11 |
| Feb ’25 | US$26.94 | US$33.09 +22.8% | 12.6% | US$42.00 | US$25.00 | n/a | 11 |
| Jan ’25 | US$27.74 | US$33.09 +19.3% | 13.9% | US$42.00 | US$25.00 | n/a | 11 |
| Dec ’24 | US$24.29 | US$33.09 +36.2% | 13.9% | US$42.00 | US$25.00 | n/a | 11 |
| Nov ’24 | US$24.54 | US$33.10 +34.9% | 14.6% | US$42.00 | US$25.00 | US$26.47 | 10 |
| Oct ’24 | US$28.01 | US$36.67 +30.9% | 15.0% | US$49.00 | US$30.00 | US$28.83 | 9 |
| Sep ’24 | US$29.27 | US$36.67 +25.3% | 15.0% | US$49.00 | US$30.00 | US$28.45 | 9 |
| Aug ’24 | US$28.54 | US$36.67 +28.5% | 14.0% | US$48.00 | US$30.00 | US$26.86 | 9 |
| Jul ’24 | US$31.30 | US$36.22 +15.7% | 13.9% | US$48.00 | US$30.00 | US$24.39 | 9 |
| Jun ’24 | US$29.28 | US$35.10 +19.9% | 13.6% | US$48.00 | US$30.00 | US$23.40 | 10 |
| May ’24 | US$28.64 | US$34.80 +21.5% | 14.3% | US$48.00 | US$30.00 | US$24.01 | 10 |
| Apr ’24 | US$28.19 | US$33.20 +17.8% | 15.1% | US$45.00 | US$27.00 | US$27.24 | 10 |
| Mar ’24 | US$27.38 | US$33.20 +21.3% | 15.1% | US$45.00 | US$27.00 | US$30.24 | 10 |
| Feb ’24 | US$28.69 | US$32.30 +12.6% | 14.3% | US$42.00 | US$27.00 | US$26.94 | 10 |
| Jan ’24 | US$26.13 | US$31.20 +19.4% | 11.9% | US$36.00 | US$26.00 | US$27.74 | 10 |
| Dec ’23 | US$25.20 | US$31.60 +25.4% | 11.6% | US$36.00 | US$26.00 | US$24.29 | 10 |
| Nov ’23 | US$23.25 | US$30.80 +32.5% | 12.0% | US$35.00 | US$25.00 | US$24.54 | 10 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$55.86
7D
-5.2%
1Y
8.0%
Teva Pharmaceutical Industries
US$19.3b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$17.08
7D
2.0%
1Y
80.5%
Collegium Pharmaceutical
US$967.5m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.41
7D
0.5%
1Y
17.1%